Eisai reports ¥41.1 bn Leqembi revenue for first half of fiscal 2025

Eisai Co., Ltd. today reported preliminary global revenue for its anti-amyloid-beta protofibril antibody, Leqembi (lecanemab), totaling ¥41.1 billion for the first half of fiscal year 2025 (April 1 to September 30, 2025). This unaudited figure highlights strong performance across key markets.

Geographically, the United States contributed ¥19.3 billion, Japan ¥11.7 billion, and China ¥7.9 billion. The Chinese revenue includes an impact from distributor stockpiling in the first fiscal quarter due to tariff risk. This preliminary data coincides with Biogen Inc.'s third-quarter 2025 financial results announcement.

Eisai's detailed financial results for its second quarter of fiscal year 2025, which will include comprehensive Leqembi revenue information, are scheduled for release on November 5, 2025. Eisai leads the global development and regulatory submissions for lecanemab, co-commercializing and co-promoting the product with Biogen Inc., while retaining final decision-making authority.